endosergЭндокринная хирургияEndocrine Surgery2306-35132310-3965Типография «Печатных дел Мастер»10.14341/2306-3513-2009-1-14-16endoserg-3987Research ArticleСтатьиArticlesАдренокортикальный ракAdrenokortikal'nyy rakBel'tsevichD G-KuznetsovN S-VanushkoV E-20091503200931№1 (2009)1416Copyright © Bel'tsevich D.G., Kuznetsov N.S., Vanushko V.E., 20092009Bel'tsevich D.G., Kuznetsov N.S., Vanushko V.E.Bel'tsevich D.G., Kuznetsov N.S., Vanushko V.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surg-endojournals.ru/jour/article/view/3987
Адренокортикальный рак (АКР) редкое заболевание, до настоящего момента характеризующееся поздним сроком выявления и неблагоприятным лечебным прогнозом.
ReferencesCrucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. — The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. 1996 Surgery 119:161-170Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. — The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. 1996 Surgery 119:161-170Dackiw AP, Lee JE, Gagel RF, Evans DB Adrenal cortical carcinoma. 2001 World J Surg 25:914-926Dackiw AP, Lee JE, Gagel RF, Evans DB Adrenal cortical carcinoma. 2001 World J Surg 25:914-926Ng L, Libertino JM Adrenocortical carcinoma: diagnosis, evaluation and treatment. 2003 J Urol 169:5-11Ng L, Libertino JM Adrenocortical carcinoma: diagnosis, evaluation and treatment. 2003 J Urol 169:5-11Al-Hawary MM, Francis IR, Korobkin M Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. 2005 Best Pract Res Clin Endocrinol Metab 19:277-292.Al-Hawary MM, Francis IR, Korobkin M Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. 2005 Best Pract Res Clin Endocrinol Metab 19:277-292.Hamrahian AH, loachimescu AG, Remer EM, Motta-Ramirez G, Boga-bathina H, Levin HS, Reddy S, Gill IS, Siperstein A, Bravo EL Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. ] 2005Clin Endocrinol Metab 90:871-877Hamrahian AH, loachimescu AG, Remer EM, Motta-Ramirez G, Boga-bathina H, Levin HS, Reddy S, Gill IS, Siperstein A, Bravo EL Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. ] 2005Clin Endocrinol Metab 90:871-877Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Goodsitt M Delayed enhanced CT for differentiation of benign from malignant adrenal masses. 1996 Radiology 200:737-742Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Goodsitt M Delayed enhanced CT for differentiation of benign from malignant adrenal masses. 1996 Radiology 200:737-742Langer P, Cupisti K, Bartsch DK, Nies C, Goretzki PE, Rothmund M, Roher HD Adrenal involvement in multiple endocrine neoplasia type 1. 2002 World J Surg 26:891-896Langer P, Cupisti K, Bartsch DK, Nies C, Goretzki PE, Rothmund M, Roher HD Adrenal involvement in multiple endocrine neoplasia type 1. 2002 World J Surg 26:891-896Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. 2001 Cancer Res 61:6762-6767Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. 2001 Cancer Res 61:6762-6767Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le Bouc Y Rearrangements at the llplS locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical rumors. 1994 J Clin Endocrinol Metab 78:1444-1453Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le Bouc Y Rearrangements at the llplS locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical rumors. 1994 J Clin Endocrinol Metab 78:1444-1453Gicquel C, Le Bouc Y Molecular markers for malignancy in adrenocortical tumors.1997 Horm Res 47:269-272Gicquel C, Le Bouc Y Molecular markers for malignancy in adrenocortical tumors.1997 Horm Res 47:269-272Wooten MD, King DK Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. 1993 Cancer 72:3145-3155Wooten MD, King DK Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. 1993 Cancer 72:3145-3155Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. 1998 Cancer 83:2194-2200Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. 1998 Cancer 83:2194-2200Terzolo M, Daffara F, Rossetto R, Buci L, Tagliabue M, Carbone V, Ciuti R, Ferruzzi P, Berruti A, Arvat E, Angeli A, Mannelli M Adjuvant mitotane therapy for adrenal cancer. 2003 Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, , p 571Terzolo M, Daffara F, Rossetto R, Buci L, Tagliabue M, Carbone V, Ciuti R, Ferruzzi P, Berruti A, Arvat E, Angeli A, Mannelli M Adjuvant mitotane therapy for adrenal cancer. 2003 Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, , p 571Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K, Eriksson В Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. 2000 Ann Oncol 11:1281-1287Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K, Eriksson В Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. 2000 Ann Oncol 11:1281-1287Khan TS, Sundin A, Juhlin C, Wilander E, Oberg K, Eriksson В Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. 2004 Med Oncol 21: 167-177Khan TS, Sundin A, Juhlin C, Wilander E, Oberg K, Eriksson В Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. 2004 Med Oncol 21: 167-177Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. 1990 J Histochem Cytochem 38:1277-1287Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. 1990 J Histochem Cytochem 38:1277-1287Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. 1992 Surgery 112:981-986Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. 1992 Surgery 112:981-986Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I Expression of a multidrug resistance gene in human cancers. -1989 J Natl Cancer Inst 81:116-124Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I Expression of a multidrug resistance gene in human cancers. -1989 J Natl Cancer Inst 81:116-124Fridborg H, Larsson R, Juhlin C, Rastad J, Akerstrom G, Backlin K, Nygren P P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. -1994 An-ticancer Res 14:1009-1016Fridborg H, Larsson R, Juhlin C, Rastad J, Akerstrom G, Backlin K, Nygren P P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. -1994 An-ticancer Res 14:1009-1016Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. 1993 Eur J Cancer 29A:1036-1038.Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. 1993 Eur J Cancer 29A:1036-1038.E.Fox, S.E Bates. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Review of Anticancer Therapy, Volume 7, Number 4, April 2007 , pp. 447-459(13).E.Fox, S.E Bates. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Review of Anticancer Therapy, Volume 7, Number 4, April 2007 , pp. 447-459(13).Walker J, Martin C, Callaghan R Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. 2004 Eur J Cancer 40:594-605Walker J, Martin C, Callaghan R Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. 2004 Eur J Cancer 40:594-605
The authors declare that there are no conflicts of interest present.